Stocktoria
Estrella Immunopharma, Inc. ESLA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-07-19
Chart by TradingView
1/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$13.1M | -$7.3M | -$11.1M | -$1.6M | -$249,146 |
| Net income | -$13.1M | -$7.3M | -$11.1M | -$996,104 | -$247,718 |
| Operating cash flow | -$1.8M | -$16.1M | -$1.3M | -$1.0M | -$316,158 |
| Total assets | $3.2M | $4.5M | $3.0M | $9.7M | $45.8M |
| Total liabilities | $13.5M | $180,701 | $9.8M | $2.7M | $1.6M |
| Shareholders' equity | -$10.4M | $4.3M | -$11.7M | -$6.5M | -$1.0M |
| Ratios | |||||
| Return on assets | -411.2% | -164.2% | -367.0% | -10.2% | -0.5% |
| Return on equity | 126.0% | -171.1% | 94.7% | 15.4% | 24.6% |
| Current ratio | 0.12 | 24.65 | 0.28 | 0.05 | 8.42 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 62,795 | $66,563 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001844417 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.